AVALANCHE BIOTECHNOLOGIES IN - COM (AAVL)

CUSIP: 05337G107

Q4 2015 13F Holders as of 31 Dec 2015

Type / Class
Equity / COM
Total 13F shares
16,069,217
Share change
-1,387,433
Total reported value
$152,980,086
Put/Call ratio
167%
Price per share
$9.52
Number of holders
74
Value change
-$11,207,736
Number of buys
31
Number of sells
49

Quarterly Holders Quick Answers

What is CUSIP 05337G107?
CUSIP 05337G107 identifies AAVL - AVALANCHE BIOTECHNOLOGIES IN - COM in SEC institutional holdings data.

Need full ownership history?
Open the full security ownership history page.

Institutional Holders of AVALANCHE BIOTECHNOLOGIES IN - COM (AAVL) as of Q4 2015

As of 31 Dec 2015, AVALANCHE BIOTECHNOLOGIES IN - COM (AAVL) was held by 74 institutional shareholders that filed Form 13F with the SEC. Together, they reported ownership of 16,069,217 shares. The largest 10 holders included FMR LLC, CADIAN CAPITAL MANAGEMENT, LP, NUMERIC INVESTORS LLC, VHCP Management, LLC, BlackRock Fund Advisors, AXA, BALYASNY ASSET MANAGEMENT LLC, VANGUARD GROUP INC, BlackRock Institutional Trust Company, N.A., and PRIMECAP MANAGEMENT CO/CA/. This page lists 74 institutional shareholders reporting positions in this security for the Q4 2015 filing period.
Investor Option Weight % Change % Value $ * Price Shares Share Change Activity Report Period
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.